Clinical Trial Update: Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for low molecular weight heparin with a soft-mist inhaler in COVID-19–related hypoxemia shows completed Phase 2/3 testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Acute Respiratory Distress Syndrome
• Hypoxemia

Drugs mentioned

• Low molecular weight heparin with soft-mist inhaler (low molecular weight heparin)

Snippet

Sponsor: Istanbul University | Conditions: COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia | Phase 2, Phase 3 | Status: COMPLETED